Relapse prevention in first-episode schizophrenia - Maintenance vs intermittent drug treatment with prodrome-based early intervention: Results of a randomized controlled trial within the German research network on schizophrenia

Journal of Clinical Psychiatry

Volumn 72, Issue 2, 2011, Pages 205-218

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   Wölwer, Wolfgang ^a   Klimke, Ansgar ^b   Eickhoff, Matthias ^c   Von Wilmsdorff, Martina ^a   Lemke, Matthias ^d   Heuser, Isabella ^e   Maier, Wolfgang ^f   Huff, Wolfgang ^g   Schmitt, Andrea ^h   Sauer, Heinrich ⁱ   Riedel, Michael ^j   Klingberg, Stefan ^k   Köpcke, Wolfgang ^l   Ohmann, Christian ^a   Möller, Hans Jürgen ^j  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Department of Psychiatry and Psychotherapy ^*  (Germany)

^c Department of Psychiatry   (Germany)

^d Heinrich Sengelmann Hospital   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k UNIVERSITY OF TÜBINGEN   (Germany)

^l UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EARLY INTERVENTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; GERMANY; HAMILTON SCALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HALOPERIDOL; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 79951981601     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05459yel     Document Type: Article

References (44)

1. National Institute for Clinical Excellence (NICE). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance; TA43. http://guidance.nice.org.uk/TA43. 2002.
2. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry. 2004;161(suppl):1-56.
3. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for the Treatment of Schizophrenia and Related Disorders. Aust N Z J Psychiatry. 2005;39(1-2):1-30.
4. Gaebel W, Falkai P, Weinmann S, et al. Behandlungsleitlinie Schizophrenie. In: S3 Praxisleitlinien in Psychiatrie und Psychotherapie. edited by Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Darmstadt, Germany: Steinkopf Verlag; 2005
5. Chan SS, Ungvari GS. Maintenance therapy in schizophrenia: a critical comment. Int J Neuropsychopharmacol. 2002;5(3):277-281.
6. Kane JM. Schizophrenia. N Engl J Med. 1996;334(1):34-42.
7. van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998;155(4):565-567.
8. Gaebel W, Jänner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res. 2002;53(1-2):145-159. doi:10.1016/S0920-964(01)0182-7 PubMed (Pubitemid 33139783)
9. Wölwer W, Buchkremer G, Häfner H, et al. German Research Network on Schizophrenia: bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci. 2003;253(6):321-329.
10. Gaebel W, Möller HJ, Buchkremer G, et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(2):129-140.
11. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed (Pubitemid 29125132)
12. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835-1842. doi:10.176/api.ajp.158. 1.1835 PubMed (Pubitemid 33054776)
13. Wunderink L, Nienhuis FJ, Sytema S, et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-661. doi:10.408/JCP. v68n0502 PubMed (Pubitemid 46841847)
14. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry. 1999;156(2):299-303.
15. Möller HJ, Riedel M, Jäger M, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol. 2008;11(7):985-997.
16. Gaebel W, Riesbeck M, Wölwer W, et al; German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007;68(11):1763-1774. doi:10.408/JCP.v68n16 PubMed (Pubitemid 350247506)
17. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) rating manual. Soc Behav Sci Doc. 1986;17:28-29.
18. Guy W, ed. Clinical Global Impressions (CGI) Scale. In: ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Dept Health, Education, and Welfare; 1976:218-222.
19. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
21. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251. doi:10.1016/0920-964(90)905-R PubMed (Pubitemid 20228720)
22. Müller MJ, Marx-Dannigkeit P, Schlösser R, et al. The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). J Psychiatr Res. 1999;33(5): 433-443. doi:10.1016/S02-3956(9)018-7 PubMed (Pubitemid 29392692)
23. Frances A, Pincus HA, First MB. The Global Assessment of Functioning Scale (GAF). In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:32.
24. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;45(212):11-19.
25. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU). The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr Scand. 1987;76(suppl):81-94.
26. Fleischhacker WW, Bergmann KJ, Perovich R, et al. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull. 1989;25(2):222-226.
27. Guy W, ed. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC: US Dept Health, Education and Welfare; 1976:534-537.
28. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry. 1996;169(4):444-450.
29. Hogan TP, Awad AG, Eastwood RA. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183. doi:10.1017/S032917050182 PubMed (Pubitemid 13132147)
30. Oliver J. The social care directive: development of a quality of life profile for use in community services for the mentally ill. Soc Work Soc Sci Rev. 1991;3:5-45.
31. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3): 133-138. doi:10.1097/04850-195090-017 PubMed (Pubitemid 26054887)
32. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980; 137(7):801-805.
33. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull. 1984;10(2):300-312.
34. Maier-Diewald W, Wittchen H-U, Hecht H, et al. Die Münchner Ereignisliste (MEL): Anwendungsmanual. Unveröffentlichtes Manuskript. Munich, Germany: Max-Planck-Institut für Psychiatrie; 1983.
35. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992.
36. Strauss JS, Carpenter WT Jr. The prognosis of schizophrenia: rationale for a multidimensional concept. Schizophr Bull. 1978;4(1):56-67.
37. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1): 16-22. doi:10.1056/NEJMoa02028 PubMed (Pubitemid 34438915)
38. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007;95(1-3):19-29. doi:10.1016/j.schres.207.06.016 PubMed (Pubitemid 47313652)
39. Kane JM, Leucht S, Carpenter D, et al; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
40. Chiles JA, Sterchi D, Hyde T, et al. Intermittent medication for schizophrenic outpatients: who is eligible? Schizophr Bull. 1989;15(1):117-121.
41. Veen ND, Selten JP, van der Tweel I, et al. Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004;161(3):501-506. doi:10.176/api.ajp.161. 3.501 PubMed (Pubitemid 38326105)
42. Diederich NJ, Goetz CG. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology. 2008;71(9): 677-684.
43. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222. doi:10.176/api.ajp.160.7.1209 PubMed (Pubitemid 41070936)
44. Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J Clin Psychiatry. 2009;70(4):477-486.